Hypoactive Sexual Desire Disorder
📧 Sign up to get email alerts when something new happens for Hypoactive Sexual Desire Disorder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: Transdermal Testosterone Gel for Female Sexual Interest and Arousal Disorder in Peri- and Post Menopause [NA]
Clinical trial update on transdermal testosterone gel for female sexual interest/arousal disorder in peri- and postmenopausal women; the stu…
-
CLINICAL_TRIALS trial_result · 2026-01-26Clinical Trial Update: Hypoactive Sexual Desire Disorder in Males [Phase 2]
A Phase 2 clinical trial for hypoactive sexual desire disorder in males was terminated, with the study sponsor listed as Mohit Khera and the…
-
FDA approval · 2025-12-13FDA Approved: ADDYI — Supplemental Application (Sprout Pharmaceuticals, Inc.)
The FDA approved a supplemental application for ADDYI (flibanserin) submitted by Sprout Pharmaceuticals.
-
CLINICAL_TRIALS research · 2025-11-04Clinical Trial Update: A Study of Flibanserin in Breast Cancer Survivors on Tamoxifen or Aromatase Inhibitors [Phase 2]
Phase 2 clinical trial evaluating flibanserin for hypoactive sexual desire disorder in breast cancer survivors on tamoxifen or aromatase inh…
-
CLINICAL_TRIALS research · 2025-07-04Clinical Trial Update: Radicle Revive 24: A Study of Health and Wellness Products on Menopausal Health and Related Health Outcomes [NA]
A completed clinical trial evaluating Radicle Revive 24 health and wellness products for menopausal health and related outcomes, including s…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA label_change · 2025-01-21FDA Approved: ADDYI — Supplemental Application (Sprout Pharmaceuticals, Inc.)
The FDA approved a supplemental application for ADDYI (flibanserin) filed by Sprout Pharmaceuticals, resulting in updated labeling for the p…
-
CLINICAL_TRIALS trial_result · 2024-11-13Clinical Trial Update: A Phase 3, Bridging, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (With or Without Decreased Arousal) [Phase 3]
Phase 3 trial of subcutaneously administered Bremelanotide in premenopausal women with Hypoactive Sexual Desire Disorder has completed.
-
CLINICAL_TRIALS research · 2024-11-13Clinical Trial Update: An Open-Label Study of 50 Mg Oral Testosterone Undecanoate (Kyztrex) in Menopausal Women with Low Testosterone and HSDD [Phase 2]
Open-label Phase 2 study evaluating 50 mg oral testosterone undecanoate (Kyztrex) in menopausal women with hypoactive sexual desire disorder…
-
CLINICAL_TRIALS trial_result · 2024-08-09Clinical Trial Update: Role of the Melanocortin-4 Receptor in Hypoactive Sexual Desire Disorder [Phase 4]
A Phase 4 clinical trial examining the role of the melanocortin-4 receptor in hypoactive sexual desire disorder has completed, with results …
-
CLINICAL_TRIALS trial_result · 2024-05-16Clinical Trial Update: Effects of Flibanserin on the Pre- and Post-menopausal Female Brain [NA]
This terminated trial evaluated the effects of flibanserin on the brain of pre- and post-menopausal women with hypoactive sexual desire diso…
-
CLINICAL_TRIALS research · 2022-10-13Clinical Trial Update: A Mindfulness-based Intervention for Older Women With Low Sexual Desire [NA]
A completed clinical trial evaluating a mindfulness-based intervention for older women with hypoactive sexual desire disorder and sexual dys…
-
CLINICAL_TRIALS trial_result · 2022-06-13Clinical Trial Update: Flibanserin (Addyi®) vs. Flibanserin and Sex Therapy [Phase 4]
Phase 4 trial comparing flibanserin alone versus flibanserin with sex therapy in hypoactive sexual desire disorder; study terminated.
-
CLINICAL_TRIALS trial_result · 2021-10-29Clinical Trial Update: Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women [Phase 3]
Phase 3 clinical trial update on LibiGel for hypoactive sexual desire disorder in postmenopausal women reports safety and efficacy results.
-
FDA approval · 2021-09-29FDA Approved: ADDYI — Supplemental Application (Sprout Pharmaceuticals, Inc.)
The FDA approved a supplemental application for ADDYI (flibanserin) from Sprout Pharmaceuticals, resulting in an updated labeling for the pr…
-
CLINICAL_TRIALS trial_result · 2021-04-09Clinical Trial Update: Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) [Phase 3]
Phase 3 trial of prasterone (DHEA) for hypoactive sexual desire disorder has completed.
-
CLINICAL_TRIALS trial_result · 2021-01-28Clinical Trial Update: 2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder [Phase 3]
Phase 3 clinical trial evaluating the efficacy and safety of bremelanotide for hypoactive sexual desire disorder in premenopausal women has …
-
CLINICAL_TRIALS trial_result · 2020-12-23Clinical Trial Update: 1. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder [Phase 3]
Phase 3 trial evaluating the efficacy and safety of Bremelanotide in premenopausal women with hypoactive sexual desire disorder has complete…
-
FDA approval · 2020-10-23FDA Approved: VYLEESI — Supplemental Application (Cosette Pharmaceuticals, Inc.)
FDA approves Cosette Pharmaceuticals' supplemental application for VYLEESI (bremelanotide), a treatment for hypoactive sexual desire disorde…
-
CLINICAL_TRIALS withdrawal · 2020-07-31Clinical Trial Update: Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) - Second Study [Phase 3]
A Phase 3 clinical trial evaluating prasterone (DHEA) for hypoactive sexual desire disorder has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2020-02-11Clinical Trial Update: BP101 for Adults With Female Sexual Dysfunction [Phase 3]
Phase 3 clinical trial update for BP101 in adults with hypoactive sexual desire disorder and female sexual dysfunction has completed.
-
CLINICAL_TRIALS trial_result · 2020-01-02Clinical Trial Update: Testosterone Patch's Effects on the Cardiovascular System and Libido [Phase 4]
Phase 4 trial update on a testosterone patch assessing cardiovascular effects and libido in hypoactive sexual desire disorder.
-
FDA label_change · 2019-10-09FDA Approved: ADDYI — Supplemental Application (Sprout Pharmaceuticals, Inc.)
The FDA approved a supplemental application for ADDYI (flibanserin) from Sprout Pharmaceuticals, updating the drug's labeling.
-
CLINICAL_TRIALS trial_result · 2019-07-12Clinical Trial Update: Bupropion in Sexual Dysfunction Among Methadone Maintenance Treatment Men [Phase 2]
Phase 2 trial investigating bupropion for sexual dysfunction in men on methadone maintenance; study completed with results posted in 2019.
-
FDA approval · 2019-06-21FDA Approved: VYLEESI — Original Application (Cosette Pharmaceuticals, Inc.)
FDA approved VYLEESI (bremelanotide) under an original NDA for the treatment of hypoactive sexual desire disorder in premenopausal women.
-
FDA approval · 2019-04-11FDA Approved: ADDYI — Supplemental Application (Sprout Pharmaceuticals, Inc.)
FDA approved a supplemental application for ADDYI (flibanserin) submitted by Sprout Pharmaceuticals.